Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays

Journal: Journal of Biochemistry & Molecular Medicine  Web

Published: July 21, 2019 Volume: 1 Issue: 2 Pages: 41-53

ISSN: 2641-6948

Authors: Thomas Charles Slade, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal and Snehasis Jana

Citation: Slade TC, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2019) Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays. J Biochem Mol Med, 1(2): 41-53.

  • 16 Views
  • Downloads

Abstract

Dysfunction of vital organs is the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Healing Treated test formulation on the function of vital organs in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Thomas Charles Slade, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like the untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) and BT-Med + BT-TI groups showed 74.4% (at 10 µg/mL) and 73.7% (at 1 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 76.4% (at 10 µg/mL) and 87.5% (at 1 µg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 209.5%, 757.8% and 836.2% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively, at 1 µg/mL compared to the untreated. Alkaline phosphatase (ALP) level was significantly increased by 71.7%, 71.9% and 56.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human bone osteosarcoma cells (MG-63) at 50 µg/mL compared to the untreated. Additionally, the level of ALP was also significantly increased by 124.9% and 106.3% in the BT-Med + BT-TI group at 25 and 50 µg/mL, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 88.3% and 75.5% in the BT-Med + BT-TI group at 1 and 10 µg/mL, respectively; while 82.8% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 47.5%, 79.8% and 94% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 67.4%, 60.8% and 80.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL; while 137% (at 0.1 µg/mL) in the BT-Med + BT-TI group as compared to the untreated group. Serotonin level was significantly increased by 225.7% (at 1 µg/mL), 176.1% (at 25 µg/mL) and 175.7% (at 63 µg/mL) in the BT-Med + BT-TI group; while 317.9% (at 1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 195.3% (at 1 µg/mL), 176.2% (at 10 µg/mL) and 194.7% (at 50 µg/mL) in the BT-Med + BT-TI group compared to the untreated group in MG-63 cells. Altogether data suggest that these results suggest that Biofield Energy Treated test formulation significantly protect the major organs viz. bones, heart, liver, lungs and brain and also improved their functions. Therefore, The Biofield Energy Treatment (The Trivedi Effect®) can be used as a complementary and alternative therapy against several disorders such as heart attack, heart failure, coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, asthma, pneumonia, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.

Conclusion

The study outcomes showed that the tested novel formulation was safe and non-toxic based on cell viability assay (MTT) in six different tested cells. The UT-Med + BT-TI group showed 74.4% restoration of cell viability at 10 µg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + BT-TI group showed and 87.5% (at 1 µg/mL) restoration of cell viability in human hepatoma cells (HepG2) compared to the untreated group. Besides, 209.5%, 757.8% and 836.2% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL as compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 71.7% and 71.9% in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively at 50 µg/mL in human endometrial adenocarcinoma cells (Ishikawa). The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 82.8% (at 0.1 µg/mL) and 88.3% (at 1 µg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively as compared to the untreated group in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 79.8% and 94% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 137% and 80.7% in the BT-Med + BT-TI group at 0.1 and 10 µg/mL, respectively compared to the untreated group in A549 cells. Serotonin level was significantly increased by 317.9% and 225.7% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 195.3% (at 1 µg/mL), 176.2% (at 10 µg/mL) and 194.7% (at 50 µg/mL) in the BT-Med + BT-TI group compared to the untreated group in MG-63 cells. Taking everything into account, the Biofield Energy Treatment significantly improved heart, liver, bones, neuronal and lungs functional enzyme biomarkers and also protected hepatocyte, cardiomyocyte, pneumocyte, osteocytes and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, it can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (high blood pressure, congestive heart failure, stroke, peripheral artery disease, rheumatic heart disease, valvular heart disease, carditis, congenital heart disease and venous thrombosis, thromboembolic disease, etc.), hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease) and lungs disorders (Asthma, Chronic bronchitis, Emphysema, Cystic fibrosis, Pneumonia). Further, it could be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., kidney, liver and heart transplants), hormonal imbalance, aging and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Ulcerative Colitis (UC), Dermatitis, Asthma, Irritable Bowel Syndrome (IBS), Pernicious Anemia, Multiple Sclerosis, Aplastic Anemia, Hepatitis, Graves’ Disease, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Atherosclerosis, Systemic Lupus Erythematosus (SLE), stress, etc., to improve overall health and Quality of Life.